MX2021005240A - Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer. - Google Patents

Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.

Info

Publication number
MX2021005240A
MX2021005240A MX2021005240A MX2021005240A MX2021005240A MX 2021005240 A MX2021005240 A MX 2021005240A MX 2021005240 A MX2021005240 A MX 2021005240A MX 2021005240 A MX2021005240 A MX 2021005240A MX 2021005240 A MX2021005240 A MX 2021005240A
Authority
MX
Mexico
Prior art keywords
combination
inhibitors
small molecule
cancer agents
cancer
Prior art date
Application number
MX2021005240A
Other languages
English (en)
Inventor
Pottayil Govindan Nair Sasikumar
Muralidhara Ramachandra
Girish Chandrappa Daginakatte
Kiran Aithal Balkudru
Original Assignee
Aurigene Discovery Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Tech Ltd filed Critical Aurigene Discovery Tech Ltd
Publication of MX2021005240A publication Critical patent/MX2021005240A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una composición que comprende un agente de bloqueo de CD47-SIRPa y uno o más agentes anticáncer: donde el agente de bloqueo de CD47-SIRPa está representado por el compuesto de la fórmula (I). La presente invención también se refiere a un método para tratar el cáncer en un sujeto mediante la administración de una cantidad terapéuticamente eficaz del agente de bloqueo de CD47-SIRPa representado por la fórmula (I) en combinación con uno o más agentes anticáncer.
MX2021005240A 2018-11-08 2019-11-08 Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer. MX2021005240A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841042108 2018-11-08
PCT/IB2019/059602 WO2020095256A1 (en) 2018-11-08 2019-11-08 Combination of small molecule cd-47 inhibitors with other anti-cancer agents

Publications (1)

Publication Number Publication Date
MX2021005240A true MX2021005240A (es) 2021-06-18

Family

ID=69159806

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021005240A MX2021005240A (es) 2018-11-08 2019-11-08 Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.

Country Status (14)

Country Link
US (2) US11311517B2 (es)
EP (1) EP3876931A1 (es)
JP (1) JP2022507025A (es)
KR (1) KR20210088584A (es)
CN (1) CN112930181A (es)
AU (1) AU2019375193A1 (es)
BR (1) BR112021008781A2 (es)
CA (1) CA3118843A1 (es)
EA (1) EA202190776A1 (es)
IL (1) IL282972A (es)
MX (1) MX2021005240A (es)
PH (1) PH12021550832A1 (es)
SG (1) SG11202104192TA (es)
WO (1) WO2020095256A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019138367A1 (en) * 2018-01-12 2019-07-18 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
WO2022170557A1 (en) * 2021-02-10 2022-08-18 Gnt Biotech & Medicals Corporation A pharmaceutical combination and method for overcoming immune suppression or stimulating immune response against cancer
CN113018415B (zh) * 2021-03-17 2022-07-01 遵义医科大学 一种药物组合及其应用
CN113750215B (zh) * 2021-09-24 2023-06-23 暨南大学 用于治疗肿瘤的联合药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2922607C (en) 2013-09-06 2022-08-30 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole derivatives as immunomodulators
DK3267984T3 (da) * 2015-03-10 2022-03-07 Aurigene Discovery Tech Ltd Forbindelserne 1,2,4-oxadiazol og thoadiazol som immunmodulatorer
WO2016142886A2 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
WO2016168246A1 (en) 2015-04-14 2016-10-20 The Procter & Gamble Company Solid conditioning composition
CN104804093A (zh) 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
US9650441B2 (en) 2015-09-21 2017-05-16 Erasmus University Medical Center Anti-CD47 antibodies and methods of use
EP3243522A1 (en) 2016-05-10 2017-11-15 Université Pierre et Marie Curie (Paris 6) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
WO2017194627A1 (en) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) New compounds and pharmaceutical use thereof in the treatment of cancer
WO2018047139A1 (en) * 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Compounds as modulators of tigit signalling pathway
SG10202010584XA (en) * 2016-10-20 2020-12-30 Aurigene Discovery Tech Ltd Dual inhibitors of vista and pd-1 pathways
WO2019138367A1 (en) * 2018-01-12 2019-07-18 Aurigene Discovery Technologies Limited 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways
CN111836621A (zh) * 2018-03-14 2020-10-27 奥瑞基尼探索技术有限公司 使用1,2,4-噁二唑化合物调节tigit和pd-1信号传导途径的方法

Also Published As

Publication number Publication date
JP2022507025A (ja) 2022-01-18
EA202190776A1 (ru) 2021-09-20
BR112021008781A2 (pt) 2021-08-03
CN112930181A (zh) 2021-06-08
PH12021550832A1 (en) 2021-10-04
US20220241248A1 (en) 2022-08-04
AU2019375193A1 (en) 2021-05-13
CA3118843A1 (en) 2020-05-14
SG11202104192TA (en) 2021-05-28
WO2020095256A1 (en) 2020-05-14
US20200147054A1 (en) 2020-05-14
KR20210088584A (ko) 2021-07-14
EP3876931A1 (en) 2021-09-15
US11311517B2 (en) 2022-04-26
IL282972A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
MX2021005240A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
EA202190630A1 (ru) Способы комбинированной терапии
ZA202109010B (en) Compounds and methods for the treatment of covid-19
NZ756754A (en) Combination therapy for the treatment or prevention of tumours
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
NZ726366A (en) Syk inhibitors
MX2023008453A (es) Metodos de tratamiento para el abuso de sustancias.
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
EA202190749A1 (ru) Способы комбинированной терапии
WO2019126739A8 (en) Pyrvinium pamoate anti-cancer therapies
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
MX2023001298A (es) Combinaciones para el tratamiento de cancer.
BR112018070946A2 (pt) administração de um construto biespecífico que se liga a cd33 e cd3 para uso em um método para o tratamento de leucemia mieloide
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2020007403A (es) Compuestos de tetrahidroisoquinolina.
WO2015035410A8 (en) Cancer therapy
MX2021009535A (es) Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación.
MX2021007565A (es) Composiciones y metodos para la terapia contra el cancer.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2020007066A (es) Reduccion de la expresion de beta-catenina e ido para potenciar la inmunoterapia.
PH12021550471A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
BR112022012821A2 (pt) Agente de ligação a ccr5 para tratamento de câncer metastático positivo para ccr5